Savara Inc.(SVRA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$5.26
- 52-Week Range
- $1.98 – $7.00
- YTD
- -6.74%
- IV Rank (30D)
- 48.98
- Straddle Price
- $2.77
- P/C Vol Ratio
- 0.01
- Market Cap
- $1.1B
Fair Value
+15.5% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 9.87% |
| Volatility Risk Premium | +139.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -73.6% |
| Book / Price | 14.7% |
| Debt / Equity | 0.17 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $5.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.11 |
| Bollinger Width / SMA20 | 215.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: ALKS, AMGN, GILD, REGN, RVMD, TVTX, TWST, VRTX
Blended Fair Value
$6.08
Current Price
$5.26
Deviation
+15.5%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.4× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 6 peers |
| Peer P/B | $6.08 | 100% | median 7.8× · 8 peers |
| Peer P/S | n/a | 0% | median 5.1× · 7 peers |
| Market Anchor (SMA50) | $5.29 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $1.1B
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +9.90% | 6 |
| Feb | +0.45% | 6 |
| Mar | +3.39% | 6 |
| Apr | -0.84% | 6 |
| May | +1.31% | 6 |
| Jun | +3.83% | 6 |
| Jul | +3.28% | 5 |
| Aug | -0.11% | 5 |
| Sep | -3.58% | 5 |
| Oct | -4.62% | 5 |
| Nov | +15.45% | 5 |
| Dec | +8.00% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.11
SMA 50: $5.28
SMA 200: $5.04
Current: $5.26
EMA 12: $5.15
EMA 26: $5.16
MACD: -0.0099 | Signal: 0.0189
BEARISH
ADX (14): 11.12
RANGE
+DI: 18.97
−DI: 20.07
Momentum Oscillators
RSI (14): 53.21
NEUTRAL
Stoch %K: 68.10
Stoch %D: 54.79
Williams %R: -24.29
Volume & Volatility
BB Upper: $5.38
BB Lower: $4.83
NEUTRAL
OBV: 4,051,420
Vol SMA 20: 1,597,037
Vol ROC: -43.98%
ATR: $0.27
True Range: $0.16
HV 20: 47.0%
HV 30: 42.7%
HV 60: 50.0%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:44.353000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 48.98
- IV Rank (7D)
- 94.04
- Avg IV
- 209.5%
- Straddle (30D)
- $2.77
- Straddle (7D)
- $0.97
- P/C Volume
- 0.01
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
14 DTE / 10d
—
—
pts
ATM — / Wing —
30 DTE / 10d
—
—
pts
ATM — / Wing —
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.48
- Correlation (SPY)
- 31.7%
- R²
- 0.10
- Ann. Volatility
- 57.4%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 227,140,397 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$1.53M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $1.04M | 68.12% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $302.48K | 19.74% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $155.06K | 10.12% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $18.02K | 1.18% | 2026-03-31 |
| 5 | GROUP ONE TRADING LLC Custodian | $13.10K | 0.85% | 2026-03-31 |
3 filers$629.54K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $342.89K | 54.47% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $231.50K | 36.77% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $55.15K | 8.76% | 2026-03-31 |
Insider Activity
Latest: 2026-03-20
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-20 | David L Lowrance | Chief Financial Officer | Mixed | +249,987 | $2.43 | -$16 | EDGAR |
| 2026-02-17 | Joseph S McCracken | Director | Exer (M) | +1,807 | $1.76 | $3.2K | EDGAR |
| 2025-12-19 | DAVID A RAMSAY | Director | Sell (S) | −20,000 | $6.06 | -$121.2K | EDGAR |
| 2025-12-16 | David L Lowrance | Chief Financial Officer | Mixed | −94,960 | $6.92 | -$435.7K | EDGAR |
| 2025-12-16 | Kathleen R. McCabe | Chief Legal Officer | Tax (F) | −39,350 | $6.92 | -$272.3K | EDGAR |
| 2025-12-16 | Robert Matthew Lutz | Chief Operating Officer | Tax (F) | −67,760 | $6.92 | -$468.9K | EDGAR |
| 2025-12-16 | Anne Erickson | Chief Business Officer | Tax (F) | −62,960 | $6.92 | -$435.7K | EDGAR |
| 2025-12-16 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | Mixed | −324,700 | $6.92 | -$1.35M | EDGAR |
| 2025-12-11 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | Gift (G) | −23,629 | — | EDGAR | |
| 2025-12-11 | An van Es-Johansson | Director | Award (A) | +40,000 | — | EDGAR | |
| 2025-12-11 | Richard J Hawkins | Director | Award (A) | +40,000 | — | EDGAR | |
| 2025-12-11 | Joseph S McCracken | Director | Award (A) | +40,000 | — | EDGAR | |
| 2025-12-11 | Nevan C Elam | Director | Award (A) | +40,000 | — | EDGAR | |
| 2025-12-11 | DAVID A RAMSAY | Director | Award (A) | +40,000 | — | EDGAR | |
| 2025-12-04 | Yasmine Wasfi | Chief Medical Officer | Tax (F) | −21,992 | $6.37 | -$140.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
28 insiders · @ $5.26
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Paul Edward Walker | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 2 | New Enterprise Associates 17, L.P. | 10%+ Owner | 24,471,264 | $128.72M | $4.00M | 1 | 2023-07-19 |
| 3 | Carmen Chang | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 4 | Rick Yang | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 5 | Mohamad Makhzoumi | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 6 | Ali Behbahani | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 7 | Anthony A. Jr. Florence | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 8 | Edward T Mathers | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 9 | FOREST BASKETT | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 10 | SCOTT D SANDELL | 10%+ Owner | 24,471,264 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| 11 | DAVID A RAMSAY | Director | 2,533,642 | $13.33M | $3.85M | 39 | 2025-12-19 |
| 12 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | 1,188,050 | $6.25M | -$336.5K | 21 | 2025-12-16 |
| 13 | Kathleen R. McCabe | Chief Legal Officer | 519,232 | $2.73M | $0 | 1 | 2025-12-16 |
| 14 | Robert N Neville | Chief Executive Officer | 498,028 | $2.62M | -$142.3K | 6 | 2019-12-26 |
| 15 | YURI PIKOVER | Director | 429,179 | $2.26M | $901.1K | 5 | 2018-12-14 |
| 16 | David L Lowrance | Chief Financial Officer | 393,894 | $2.07M | -$568.8K | 18 | 2026-03-20 |
| 17 | Anne Erickson | Chief Business Officer | 371,712 | $1.96M | $0 | 5 | 2025-12-16 |
| 18 | Raymond Dennis Pratt | Chief Medical Officer | 340,050 | $1.79M | $24.4K | 6 | 2024-12-16 |
| 19 | Joseph S McCracken | Director | 302,644 | $1.59M | $428.1K | 15 | 2026-02-17 |
| 20 | Badrul A. Chowdhury | CHIEF MEDICAL OFFICER | 300,000 | $1.58M | -$51.6K | 5 | 2021-12-14 |
| 21 | Robert Matthew Lutz | Chief Operating Officer | 293,977 | $1.55M | $0 | 5 | 2025-12-16 |
| 22 | Yasmine Wasfi | Chief Medical Officer | 168,008 | $883.7K | $0 | 2 | 2025-12-04 |
| 23 | Jaakko Taneli Jouhikainen | See Remarks | 167,569 | $881.4K | -$711.9K | 6 | 2019-12-26 |
| 24 | Richard J Hawkins | Director | 161,326 | $848.6K | -$205.6K | 14 | 2025-12-11 |
| 25 | Nevan C Elam | Director | 106,887 | $562.2K | -$442.3K | 15 | 2025-12-11 |
| 26 | Braden C. Parker | Chief Commercial Officer | 105,000 | $552.3K | $0 | 2 | 2024-12-16 |
| 27 | An van Es-Johansson | Director | 102,500 | $539.1K | $0 | 7 | 2025-12-11 |
| 28 | Ricky Sun | Director | 22,500 | $118.3K | $0 | 5 | 2023-12-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 6.1 |
| EV/EBITDA | -8.0 |
| TTM Net Income | $-0.1B |
| TTM EPS | $-0.56 |
| ROE | -73.6% |
| Debt/Equity | 0.17 |